How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022.

Thomas AlthausChristopher E OvertonIsabelle DevauxThomas HouseArnaud LapouzeAlexa TroelBertrand VanzoMargaux LarocheAlexandre BorderoPernille JorgensenRichard PebodyEric J Voiglio

Published in: BMC medicine (2024)

Protection conferred by the BNT162b2 mRNA vaccine against transmission and infection was low for delta and omicron BA.1&2, regardless of the number of vaccine doses and previous SARS-CoV-2 infection. There was no significant vaccine effect for omicron BA.4&5. Health authorities carrying out vaccination campaigns should bear in mind that the current generation of COVID-19 vaccines may not represent an effective tool in protecting individuals from either transmitting or acquiring SARS-CoV-2 infection.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
healthcare
public health
mental health
quality improvement
binding protein
climate change